146 related articles for article (PubMed ID: 22302337)
1. Customized adherence enhancement for individuals with bipolar disorder receiving antipsychotic therapy.
Sajatovic M; Levin J; Tatsuoka C; Micula-Gondek W; Williams TD; Bialko CS; Cassidy KA
Psychiatr Serv; 2012 Feb; 63(2):176-8. PubMed ID: 22302337
[TBL] [Abstract][Full Text] [Related]
2. Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder.
Sajatovic M; Levin J; Tatsuoka C; Micula-Gondek W; Fuentes-Casiano E; Bialko CS; Cassidy KA
Bipolar Disord; 2012 May; 14(3):291-300. PubMed ID: 22548902
[TBL] [Abstract][Full Text] [Related]
3. A 6-Month, Prospective, Randomized Controlled Trial of Customized Adherence Enhancement Versus Bipolar-Specific Educational Control in Poorly Adherent Individuals With Bipolar Disorder.
Sajatovic M; Tatsuoka C; Cassidy KA; Klein PJ; Fuentes-Casiano E; Cage J; Aebi ME; Ramirez LF; Blixen C; Perzynski AT; Bauer MS; Safren SA; Levin JB
J Clin Psychiatry; 2018 Sep; 79(6):. PubMed ID: 30256551
[TBL] [Abstract][Full Text] [Related]
4. Long-Acting Injectable Antipsychotic Medication Plus Customized Adherence Enhancement in Poor Adherence Patients With Bipolar Disorder.
Sajatovic M; Levin JB; Ramirez LF; Cassidy KA; McNamara N; Fuentes-Casiano E; Wilson B; Appling D; S FB
Prim Care Companion CNS Disord; 2021 Sep; 23(5):. PubMed ID: 34534421
[No Abstract] [Full Text] [Related]
5. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.
Amsterdam JD; Wang CH; Shwarz M; Shults J
J Affect Disord; 2009 Jan; 112(1-3):219-30. PubMed ID: 18486235
[TBL] [Abstract][Full Text] [Related]
6. Symptom severity, self-reported adherence, and electronic pill monitoring in poorly adherent patients with bipolar disorder.
Sajatovic M; Levin JB; Sams J; Cassidy KA; Akagi K; Aebi ME; Ramirez LF; Safren SA; Tatsuoka C
Bipolar Disord; 2015 Sep; 17(6):653-61. PubMed ID: 26529124
[TBL] [Abstract][Full Text] [Related]
7. Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication.
Sajatovic M; Levin J; Fuentes-Casiano E; Cassidy KA; Tatsuoka C; Jenkins JH
Compr Psychiatry; 2011; 52(3):280-7. PubMed ID: 21497222
[TBL] [Abstract][Full Text] [Related]
8. Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.
Sajatovic M; Levin J; Ramirez LF; Hahn DY; Tatsuoka C; Bialko CS; Cassidy KA; Fuentes-Casiano E; Williams TD
J Clin Psychiatry; 2013 Dec; 74(12):1249-55. PubMed ID: 24434094
[TBL] [Abstract][Full Text] [Related]
9. The relationship of gender and gender identity to treatment adherence among individuals with bipolar disorder.
Sajatovic M; Micula-Gondek W; Tatsuoka C; Bialko C
Gend Med; 2011 Aug; 8(4):261-8. PubMed ID: 21763217
[TBL] [Abstract][Full Text] [Related]
10. Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea.
Woo YS; Bahk WM; Jon DI; Chung SK; Lee SY; Ahn YM; Pae CU; Cho HS; Kim JG; Hwang TY; Lee HS; Min KJ; Lee KU; Yoon BH
Psychiatry Clin Neurosci; 2010 Feb; 64(1):28-37. PubMed ID: 19895394
[TBL] [Abstract][Full Text] [Related]
11. Associations of Comorbid Anxiety With Medication Adherence and Psychiatric Symptomatology in a Population of Nonadherent Bipolar Disorder Subjects.
Aftab A; Levin J; Aebi M; Bhat C; Sajatovic M
J Nerv Ment Dis; 2018 Apr; 206(4):258-262. PubMed ID: 29351117
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.
Suppes T; Webb A; Paul B; Carmody T; Kraemer H; Rush AJ
Am J Psychiatry; 1999 Aug; 156(8):1164-9. PubMed ID: 10450255
[TBL] [Abstract][Full Text] [Related]
13. Trajectories of medication attitudes and adherence behavior change in non-adherent bipolar patients.
Levin JB; Tatsuoka C; Cassidy KA; Aebi ME; Sajatovic M
Compr Psychiatry; 2015 Apr; 58():29-36. PubMed ID: 25617964
[TBL] [Abstract][Full Text] [Related]
14. Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder.
Kaplan BJ; Simpson JS; Ferre RC; Gorman CP; McMullen DM; Crawford SG
J Clin Psychiatry; 2001 Dec; 62(12):936-44. PubMed ID: 11780873
[TBL] [Abstract][Full Text] [Related]
15. Medication treatment perceptions, concerns and expectations among depressed individuals with Type I Bipolar Disorder.
Sajatovic M; Jenkins JH; Cassidy KA; Muzina DJ
J Affect Disord; 2009 Jun; 115(3):360-6. PubMed ID: 18996600
[TBL] [Abstract][Full Text] [Related]
16. Comparative response to electroconvulsive therapy in medication-resistant bipolar I patients with depression and mixed state.
Medda P; Perugi G; Zanello S; Ciuffa M; Rizzato S; Cassano GB
J ECT; 2010 Jun; 26(2):82-6. PubMed ID: 19710623
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder.
Han C; Lee MS; Pae CU; Ko YH; Patkar AA; Jung IK
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1219-23. PubMed ID: 17532106
[TBL] [Abstract][Full Text] [Related]
18. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence.
Rubio G; López-Muñoz F; Alamo C
Bipolar Disord; 2006 Jun; 8(3):289-93. PubMed ID: 16696832
[TBL] [Abstract][Full Text] [Related]
19. Depressive residual symptoms are associated with lower adherence to medication in bipolar patients without substance use disorder: results from the FACE-BD cohort.
Belzeaux R; Correard N; Boyer L; Etain B; Loftus J; Bellivier F; Bougerol T; Courtet P; Gard S; Kahn JP; Passerieux C; Leboyer M; Henry C; Azorin JM;
J Affect Disord; 2013 Dec; 151(3):1009-15. PubMed ID: 24051101
[TBL] [Abstract][Full Text] [Related]
20. Combination of mood stabilizers with quetiapine for treatment of acute bipolar disorder: an open label study.
Bahk WM; Yoon BH; Lee KU; Chae JH
Hum Psychopharmacol; 2004 Apr; 19(3):181-5. PubMed ID: 15079852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
